Bio-Techne enters the autumn as a cash-merger equity rather than a growth-tools story. Merck KGaA, Darmstadt, Germany agreed in late June to acquire the Minneapolis reagent and diagnostics company for $73 in cash per share through a Minnesota merger subsidiary. The fiscal year that closed at the end of June produced a flat organic top line on more than $1.2 billion of sales, so the strategic bid arrives after a year in which the public market had already compressed the growth narrative. Organic growth here means sales excluding currency, recent acquisitions, and units classified as held for sale. The remaining debate is whether Hart-Scott-Rodino clearance after an August pull-and-refile, plus a majority-of-outstanding shareholder vote later in September, converts that cash price into a completed takeout.
The operating year underneath the bid is a split franchise, not a demand failure. Large pharmaceutical accounts carried Protein Sciences while two cell-therapy customers with Fast Track designations paused manufacturing-grade reagent orders, and emerging-biotech spending lagged a rebound in funding. Diagnostics and Spatial Biology grew organically even as the Exosome Diagnostics exit and a held-for-sale unit cut the reported line. Adjusted operating margin, the non-GAAP measure that strips stock compensation, amortization, and one-time items, held in the low thirties as mix worked against Protein Sciences and cost actions plus the divestiture lifted the smaller segment. That combination is why a strategic buyer is paying a tools multiple for a year of no organic growth: the catalog, the manufacturing-grade protein position, and the spatial platform are more durable than the fiscal print.
The cash spread is now thin. Shares last traded near $72, a few dozen cents under the contracted consideration, against a pre-deal close near $59 and an earlier undisturbed print after an activist letter became public. A special meeting is set for late September. The question the next several months resolve is whether antitrust review after the August refile stays inside the ordinary waiting-period path, or whether a burdensome-condition fight or a failed majority-of-outstanding vote sends the residual claim back to a standalone tools multiple on a still-mixed end market.